EXECUTIVE ENGAGEMENTS
POOL
7883
Number of executives repeatedly engaged by snail & email outreach
INTERACTIONS
1104
Interactions with Platform & by Email
PARTICIPANTS
236
Unique # Participated
VALIDATIONS
82
Responses Validated*
COMPANIES
102
Responses Validated*
* Login for a full stack data experience
DATE
JAN 2022
TABLES
123
PAGES
224
EDITION
9
PRICE
USD 4950
CODE
MCP12538
*Engagement stats are ongoing and dynamic
RESEARCH MODULES
EXECUTIVES
Global Immuno-Oncology Market to Reach $143.9 Billion by 2026
Amid the COVID-19 crisis, the global market for Immuno-Oncology estimated at US$63.9 Billion, is projected to reach a revised size of US$143.9 Billion by 2026, growing at a CAGR of 14.3% over the analysis period. Immune Checkpoint Inhibitors, one of the segments analyzed in the report, is projected to record a 14.2% CAGR and reach US$143.5 Billion by the end of the analysis period. After an thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immune System Modulators segment is readjusted to a revised 15% CAGR for the next 7-year period.
The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 13.8% CAGR
The Immuno-Oncology market in the U.S. is estimated at US$18.9 Billion, while China is forecast to reach a projected market size of US$28.4 Billion by the close of the analysis period trailing a CAGR of 13.8%. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.7% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR.
HIGHLIGHTS & REPORT INDEX
What`s New for 2022?
» Global competitiveness and key competitor percentage market shares
» Market presence across multiple geographies - Strong/Active/Niche/Trivial
» Online interactive peer-to-peer collaborative bespoke updates
» Access to our digital archives and MarketGlass Research Platform
» Complimentary updates for one year
Global Immuno-Oncology Market to Reach $143.9 Billion by 2026
Amid the COVID-19 crisis, the global market for Immuno-Oncology estimated at US$63.9 Billion, is projected to reach a revised size of US$143.9 Billion by 2026, growing at a CAGR of 14.3% over the analysis period. Immune Checkpoint Inhibitors, one of the segments analyzed in the report, is projected to record a 14.2% CAGR and reach US$143.5 Billion by the end of the analysis period. After an thorough analysis of the business implications of the pandemic and its induced economic crisis, growth in the Immune System Modulators segment is readjusted to a revised 15% CAGR for the next 7-year period.
The U.S. Market is Estimated at $18.9 Billion, While China is Forecast to Grow at 13.8% CAGR
The Immuno-Oncology market in the U.S. is estimated at US$18.9 Billion, while China is forecast to reach a projected market size of US$28.4 Billion by the close of the analysis period trailing a CAGR of 13.8%. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 12.7% and 12.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.5% CAGR.
Cancer Vaccines Segment to Record 15.6% CAGR
In the global Cancer Vaccines segment, USA, Canada, Japan, China and Europe will drive the 15.4% CAGR estimated for this segment. These regional markets accounting for a combined market size of US$1.5 Billion will reach a projected size of US$4 Billion by the close of the analysis period. China will remain among the fastest growing in this cluster of regional markets.
SELECT PLAYERS
AbbVie, Inc.; Aduro BioTech, Inc.; Amgen, Inc.; AstraZeneca PLC; Bavarian Nordic A/S; Bristol-Myers Squibb Company; Celgene Corporation; Celldex Therapeutics, Inc.; Eli Lilly and Company; EMD Serono, Inc.; F. Hoffmann-La Roche AG; Galena Biopharma, Inc.; Gilead Sciences, Inc.; ImmunoCellular Therapeutics Ltd.; Incyte Corporation; Johnson & Johnson; Merck & Co., Inc.; Novartis International AG; Pfizer, Inc.; Prometheus Laboratories, Inc.; Sanofi SA
SEGMENTS
» Cancer Type (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer, Other Cancer Types) » Therapy Type (Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus, Other Therapy Types)
GEOGRAPHIES
» World » United States » Canada » Japan » China » Europe » France » Germany » Italy » United Kingdom » and Rest of Europe » Asia-Pacific » Rest of World
TABLE OF CONTENTS
| I. METHODOLOGY |
| II. EXECUTIVE SUMMARY |
| 1. MARKET OVERVIEW |
| Influencer Market Insights |
| Impact of Covid-19 and a Looming Global Recession |
| 2. FOCUS ON SELECT PLAYERS |
| 3. MARKET TRENDS & DRIVERS |
| 4. GLOBAL MARKET PERSPECTIVE |
| World Current & Future Analysis for Immuno-Oncology by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2020 & 2027 |
| World Current & Future Analysis for Immune Checkpoint Inhibitors by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Immune Checkpoint Inhibitors by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Immune System Modulators by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Immune System Modulators by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Cancer Vaccines by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Cancer Vaccines by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Oncolytic Virus by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Oncolytic Virus by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other Therapy Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Therapy Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Melanoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Melanoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Blood Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Blood Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Renal Cell Carcinoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Renal Cell Carcinoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Bladder Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Bladder Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| World Current & Future Analysis for Other Cancer Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| World 7-Year Perspective for Other Cancer Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2020 & 2027 |
| III. MARKET ANALYSIS |
| UNITED STATES |
| USA Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| USA Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| USA 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| CANADA |
| Canada Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Canada Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Canada 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| JAPAN |
| Japan Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Japan Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Japan 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| CHINA |
| China Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| China Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| China 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| EUROPE |
| Europe Current & Future Analysis for Immuno-Oncology by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Immuno-Oncology by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2020 & 2027 |
| Europe Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Europe Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Europe 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| FRANCE |
| France Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| France Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| France 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| GERMANY |
| Germany Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Germany Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Germany 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| ITALY |
| Italy Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Italy Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Italy 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| UNITED KINGDOM |
| UK Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| UK Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| UK 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| REST OF EUROPE |
| Rest of Europe Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Rest of Europe Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of Europe 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| ASIA-PACIFIC |
| Asia-Pacific Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Asia-Pacific Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Asia-Pacific 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| REST OF WORLD |
| Rest of World Current & Future Analysis for Immuno-Oncology by Therapy Type - Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Immuno-Oncology by Therapy Type - Percentage Breakdown of Value Sales for Immune Checkpoint Inhibitors, Immune System Modulators, Cancer Vaccines, Oncolytic Virus and Other Therapy Types for the Years 2020 & 2027 |
| Rest of World Current & Future Analysis for Immuno-Oncology by Cancer Type - Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types - Independent Analysis of Annual Sales in US$ Million for the Years 2020 through 2027 and % CAGR |
| Rest of World 7-Year Perspective for Immuno-Oncology by Cancer Type - Percentage Breakdown of Value Sales for Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Bladder Cancer and Other Cancer Types for the Years 2020 & 2027 |
| IV. COMPETITION |
| Total Companies Profiled: 102 |
PREVIEW REPORT
Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.
What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: Privacy@StrategyR.com